Utah Medical Products, Inc. (UTMD)

In the first quarter of 2026, consolidated sales were $987,000 lower than in Q1 2025, primarily due to the absence of sales to its previous largest medical device distributor in China and its former OEM customer, PendoTECH. On February 4, 2026, Utah Medical Products, Inc. announced a quarterly dividend. As of May 4, 2026, UTMD's stock price was $64.81, with a 52-week range of $51.80 to $71.81. On May 1, 2026, stockholders elected directors and ratified the selection of Haynie & Co. as the independent public accounting firm for 2026. Following its earnings release 40 days prior to May 10, 2026, UTMD stock drifted 3.5% higher, trading in a range between $60.05 and $68.71. In the past year, UTMD's profit was reduced by $1.4 million due to unusual items.

While there is no explicit statement detailing inherent seasonal demand patterns for Utah Medical Products, Inc.'s products and services, the company's demand has been influenced by specific events and external factors. Restrictions on "nonessential" medical procedures and changes in orders from large OEM customers have significantly impacted sales. These instances suggest that demand can be volatile due to specific customer relationships and broader economic or health-related conditions rather than predictable seasonal cycles.

Utah Medical Products, Inc. (UTMD) is a medical device company specializing in proprietary, disposable, and reusable medical devices primarily for hospital use, with a particular focus on healthcare for women and babies. The company operates within the Healthcare sector and the Medical Instruments & Supplies industry. UTMD develops, manufactures, and distributes a range of medical devices used in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices. Major products include blood pressure monitoring and blood management devices, electrosurgery products, gynecology and women's pelvic health devices, neonatal critical care and perinatology products, urology devices, and OEM products/capabilities.

UTMD's corporate headquarters are located in Midvale, Utah, USA. The company has a significant international presence, operating four facilities outside the United States in Romsey, Hampshire, England; Castle Hill, NSW, Australia; Mississauga, Ontario, Canada; and Athlone, County Westmeath, Ireland. The company has established relationships with over 300 international distributors and has representation in major developed countries and many underdeveloped countries. In 2022, 39% of consolidated total sales were to international customers, and 30% of employees are based outside the United States.

In the past year, Utah Medical Products, Inc.'s brand reputation has been impacted by ongoing product liability litigation related to its Filshie Clip System in the U.S. The company has been actively defending the "excellent reputation of the Filshie Clip System" against these lawsuits, which have led to increased legal costs in 2023 and are projected to be even higher in 2024. UTMD views these cases as being "without merit" and believes it will ultimately prevail.

As of April 8, 2026, Utah Medical Products, Inc. has 117 institutional owners and shareholders holding a total of 2,101,305 shares. Major institutional shareholders include Brandes Investment Partners, Lp, Dimensional Fund Advisors Lp, Renaissance Technologies Llc, BlackRock, Inc., Vanguard Group Inc, Hotchkis & Wiley Capital Management Llc, Minerva Advisors LLC, Geode Capital Management, Llc, State Street Corp, and Rice Hall James & Associates, Llc. Individual insiders own 7.18% of the company's shares, while institutions hold 61.7%. The general public owns 25% of the shares. Kevin Cornwell, CEO and Chairman, is a significant individual shareholder.